Literature DB >> 5720932

[Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women].

J P Garin, J Pellerat, R Woehrle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5720932

Source DB:  PubMed          Journal:  Presse Med        ISSN： 0032-7867            Impact factor:   1.228


× No keyword cloud information.
  10 in total

1.  Toxoplasmosis in pregnancy and its transmission to the fetus.

Authors:  G Desmonts; J Couvreur
Journal:  Bull N Y Acad Med       Date:  1974-02

2.  Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

Authors:  F G Araujo; D R Guptill; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 3.  Epidemiology of and diagnostic strategies for toxoplasmosis.

Authors:  Florence Robert-Gangneux; Marie-Laure Dardé
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.

Authors:  F G Araujo; R M Shepard; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

5.  Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole) and spiramycin in pregnant mice infected with Toxoplasma gondii (Beverley strain).

Authors:  B T Nguyen; S Stadtsbaeder
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

6.  Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

7.  Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the fetus.

Authors:  E Schoondermark-Van de Ven; J Galama; W Camps; T Vree; F Russel; J Meuwissen; W Melchers
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Effectiveness of spiramycin for treatment of congenital Toxoplasma gondii infection in rhesus monkeys.

Authors:  E Schoondermark-Van de Ven; W Melchers; W Camps; T Eskes; J Meuwissen; J Galama
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 9.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 10.  Management of toxoplasmosis.

Authors:  V S Georgiev
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.